JOURNAL
Current Issue
Journal Archive
...........................................
October 2008 - Volume 6 Issue 8
Download print-friendly version (970kb)
...........................................
From the Editor
........................................................
Original Contributon and Clinical Investigation

Efficacy of 3 Day Azithromycin Versus 10 Day Co-Amoxiclav in the Treatment of Children with Acute Otitis Media
Khaled Amro, MD

Investigation of Demographic and Clinical Features in 131 Iranian Patients with Cluster Headache
A.Ghorbani, MD, A.Chitsaz, MD, M.R.Savoj, MD, M. Etemadifar, MD
 
Nitroimidazoles in The Treatment of Intestinal Amoebiasis
Dr Suleiman Muneizel
Usefulness of C-reactive Protein in Diagnosis of Intrapartum and Postpartum Neonatal Sepsis
Khaled Amro, MD
........................................................
Medicine and Society
How Many People Have Cancer Patients (Alive or Deceased) in Their Homes, in Our City?
Dilek Toprak, Nurhan Dogan, Serap Demir, Gülnihal Tufan
Women Knowledge Assessment about Self Care Behavior in Shiraz Health Care Center 2006
Vizeshfar, Fatemeh- Mehdizadeh, Kadege
........................................................

Education and Training

How to Write a Scientific Paper "Publish or perish" A Motivation to Learn More
Ebtisam Elghiblawi
 
........................................................
Case Report
Heterotopic Pregnancy in Natural Cycle - Probably Not Rare
Dr.Ramadevi V Wani, Dr.Sami Al Taher
........................................................
Child-Watch section
Child-Watch Distribution of Eid Gifts to Blind Girls School
........................................................
New Media
Advances in Surgical Education - for Surgical Trainees and Family Doctors
Lesley Pocock
........................................................
New Briefs
The Medical Renaissance Movement
Dr. Michael Ellis
........................................................

Chief Editor -
Abdulrazak Abyad MD, MPH, MBA, AGSF, AFCHSE

.........................................................

Publisher -
Lesley Pocock
medi+WORLD International
572 Burwood Road,
Hawthorn 3122
AUSTRALIA
Phone: +61 (3) 9819 1224
Fax: +61 (3) 9819 3269
Email
: lesleypocock@mediworld.com.au
.........................................................

Editorial Enquiries -
abyad@cyberia.net.lb
.........................................................

Advertising Enquiries -
lesleypocock@mediworld.com.au
.........................................................

While all efforts have been made to ensure the accuracy of the information in this journal, opinions expressed are those of the authors and do not necessarily reflect the views of The Publishers, Editor or the Editorial Board. The publishers, Editor and Editorial Board cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; or the views and opinions expressed. Publication of any advertisements does not constitute any endorsement by the Publishers and Editors of the product advertised.

The contents of this journal are copyright. Apart from any fair dealing for purposes of private study, research, criticism or review, as permitted under the Australian Copyright Act, no part of this program may be reproduced without the permission of the publisher.

October 2008 - Volume 6, Issue 8

Efficacy of 3 Day Azithromycin Versus 10 Day Co-Amoxiclav in the Treatment of Children with Acute Otitis Media

.........................................................................................................................
Khaled Amro, MD*

*Pediatrician from department of pediatric
In Royal Medical Services-Jordan


ABSTRACT

Objective: To compare the use of Azithromycin and co-Amoxiclav in the treatment of symptoms and signs of acute suppurative otitis media in children.

Methods: Children of four months to 12 years of age, attended out-patient Pediatric and ENT clinics at Prince Hashim bin Al Hussain Hospital in AZ-Zarqa (JORDAN) from June 2006 to June 2007; with signs and symptoms of acute suppurative otitis media, were enrolled in the study. Patients were randomized to receive either Azithromycin 10 mg/kg/day in a single dose for 3 days or co-Amoxiclav 45 mg/kg/day in three divided doses for 10 days. Clinical improvement was evaluated on the 2nd and 4th weeks after therapy.

Results: Satisfactory clinical response was measured regarding symptoms and signs two weeks after the beginning of therapy. They were 84.6% for Azithromycin and 88% for Co-Amoxiclav. At day 28, 61 patients (82.4%) were cured on Azithromycin compared with 66 patients (83.5 %) on Co-Amoxiclav.

Conclusion: Azithromycin given for three days and Co-Amoxiclav for ten days had similar efficacy; however, Azithromycin was better tolerated.

Key words: Acute Suppurative Otitis Media, Children, Antibiotics.

 

INTRODUCTION

Otitis Media is an inflammation in the middle ear. Subcategories include acute otitis media, otitis media with effusion (also known as "glue ear"), recurrent acute otitis media, and chronic suppurative otitis media. Acute otitis media presents with systemic and local signs and has a rapid onset. The persistence of an effusion beyond three months without signs of infection defines otitis media with effusion, whereas chronic suppurative otitis media is characterized by continuing inflammation in the middle ear giving rise to otorrhoea and a perforated tympanic membrane(1).

Our study is on Acute Suppurative Otitis Media (ASOM), which is a suppurative infection of the middle ear cavity and is most common in healthy children between 6 months and 2 years of age, it is more common in boys, in patients of lower socioeconomic status, in formula fed infants, and in the winter months(2). It is an important health problem in early childhood, and is the most frequent condition for which antibiotics are prescribed in the USA(3).

The most common pathogens are streptococcus pneumonic Hemophilus Influenza, and Branhamella catarrhal; half of these organisms are B-lactamase producers. Very young children will not complain of pain but will be irritable and may bang the head on the cot sides. On examination, the young child is febrile, restless and uncooperative with red, bulging tympanic membrane. If the ears discharge, it is usually blood stained initially and this may worry parents.

The discharge then becomes mucopurulent(4). A combination of important factors contributes to pathogenesis of ASOM. The most two important factors in children are Eustachian tube dysfunction and the child susceptibility to recurrent upper respiratory tract infections. In the child, the Eustachian tube is shorter (less distance for organisms to travel), placed horizontal (inadequate drainage of middle ear) and has adenoids present at the opening, which can readily block the tube and serve as a reservoir of infection.

Bacteria are responsible for the majority of cases(5). Antibiotic treatment of Acute Suppurative Otitis Media hastens symptomatic relief and potentially prevents the development of more serious invasive disease(6). As there are a number of antibiotics used for this purpose we undertook this trial in children with ASOM to compare the use of two important antibiotics commonly used in this condition in Jordan.

Amoxicillin semi synthetic penicillin has broadened spectra against Gram-negatives and is effective orally. Amoxicillin plus Clavulanate is Clavamox or Augmentin. The Clavulanate is not an anti- microbial agent; it inhibits beta-lactamase enzymes and has given extended life to penicillinase(7). Generally ampicillin, amoxicillin, or co-Amoxiclav (amoxicillin-clavulanate) are preferred and most commonly used in ASOM in Jordan.

Azithromycin is an azolide antibiotic. It is active in vitro against a variety of microorganisms and has a greater distribution in tissues, a longer elimination half-life and a lower incidence of adverse effects than Erythromycin(8). The purpose of this study was to compare the clinical use of Azithromycin with Amoxiclav.


METHODS

This consecutive study was carried out at PrinceHashim Hospital in AZ-Zarqa city in Jordan from June 2006 to June 2007, on children attending outpatient ENT and pediatric OPD clinics. Children of ages four months to twelve years were enrolled in the study, if they satisfied one or more of the following criteria:

  • Ear pain or fullness.
  • Decreased hearing.
  • Discharge from the external auditory canal.
  • Bulging or marked injection of the tympanic membrane.
  • Loss of the normal light reflex or tympanic membrane landmarks.
  • As well as generalized symptoms; fever, general malaise, and irritability.

Exclusion criteria included: History of Macrolide or B-lactamase drug allergy, history of antibiotic treatment in the preceding four weeks, Symptoms persisting for more than four weeks, and children receiving antimicrobial prophylaxis.

Patients were randomized on alternative weeks and accordingly divided into two groups: First group received either Azithromycin (10 mg/kg/day) once daily for three days, and second group were given Co-Amoxiclav (45mg/kg/day) in three divided doses for ten days.
Assessment of these patients was carried out on the initial visits and follow up was done on days 14 and 28.

Patients were identified to be cured when there was a complete resolution of all signs and symptoms, improved by partial resolution of signs and symptoms, and failed, if there were no changes or worsening of symptoms and signs.

On follow up visits complete Ear, Nose and Throat examination was performed by the same physicians at all pre treatment and post treatment visits.


RESULTS

Two hundred and three patients were initially enrolled in the study. 17 patients were non-eligible as 5 had allergy to Amoxicillin, and 12 didn't fulfill the inclusion criteria because they received antibiotics in the preceding four weeks. The total number of patients found eligible in our study was 186 children. All of these patients were randomized into two groups; the first group included 91 children (received Azithromycin 10mg/kg/day once daily for three days), while the second group included 95 children and were given Co-Amoxiclav 45 mg/kg/day in three divided doses for 10days). The mean age of patients enrolled was 3.4 years (range 4 months-12 years).

The most common symptom was ear pain (94%) while the most common sign was of injection tympanic membrane (93%). (Table I) Patients' post treatment evaluation was done at two weeks; in the first group, 66 out of 78 children (84.6%) showed improvement or were cured, compared to 74 out of 84 children (88%) in the second group.

However, at four weeks post treatment, 61 out 74 children (82.4%) in the first group were completely cured and did not need any further antibiotic treatment, compared again to 66 out of 69 children (83.5%) in the second group. (Table II, Figure 1)

Regarding the adverse effects to the drugs used, these were mostly seen in children treated with Co-Amoxiclav compared with those who received Azithromycin and occurred in18% and 10% respectively. The most commonly observed side effect with both drugs was diarrhea. Rash and vomiting were also seen.

Table 1: Signs and symptoms found at presentation
Signs and symptoms Number     %
Ear pain or fullness       175     94
Decrease hearing       23     12.3
Discharge from external auditory canal       13      7
Injection of tympanic membrane       172      93
Bulging of tympanic membrane       98     47.8
Perforated tympanic membrane        9      4.8
Generalized symptoms, fever, general malaise and irritability       69      37

 

Table 2: Response after two and four weeks
  Azithromycin   % Co-Amoxiclav %
Response at two weeks cured and/or improved 66/78 84.6      74/84 88
Response at four weeks cured and/or improved 61/74 82.4      66/79 83.5

Fig. 1 Total number of patients

 

DISCUSSION

In Jordan, particularly the Royal Medical Services, Acute Suppurative Otitis Media is usually treated with antibiotics, and generally amoxicillin, or Co-Amoxiclav (amoxicillin-clavulanate) are preferred and this depends on the availability and the cost of these medications. In his study, Dunne MW et al have provided evidence that Azithromycin for three days of treatment with a total dose of 30 mg/kg/day is as effective as Co-Amoxiclav given at 45 mg/kg/day. Similarly our study carried out on children of various age groups showed that the success rate of treatment at 2 and 4 weeks was nearly equivalent for both antibiotics and there was no significant difference (Table II).

Satisfactory clinical response regarding symptoms and signs evaluated at 2 weeks post treatment was 84.6% for Azithromycin and 88% for Co-Amoxiclav; this is compared to results seen in the Dunne et al study where the clinical success (cure and improvement) in all subjects was 83% for Azithromycin group of patients, and 88% for patients on Co-Amoxiclav on evaluation at 10 days post treatment. However regarding Co- Amoxiclav, it was noted that it led to a quicker resolution of tympanic membrane signs such as bulging and loss of landmarks at two weeks after initiation of treatment, whereas at four weeks of treatment both agents showed a similar outcome.

As for the mechanism of action, Co-Amoxiclav is a bactericidal agent whereas Azithromycin is a protein synthesis inhibitor (bacteristatic) agent; it is an azolide antibiotic, which has a greater distribution in tissues, a longer elimination half-life, and a lower incidence of adverse effects, than erythromycin. These pharmacokinetic features allow once-daily dosing and a shorter duration of therapy(9,10).

Our diagnoses were based on acute signs of infection and eardrum abnormalities, which is in keeping with the day-to-day practice in our hospital (The Royal Medical Services). There is a considerable controversy as to what antibiotic to use if at all, as some studies showed that up to 80% of cases with ASOM would resolve within one week without antibiotic treatment. The generalized use of antibiotics in this condition increases health care costs and creates numerous side effects(10). Watchful waiting at the first visit was justified by Damoiseaux et al for children aged 6-24 months with ASOM(11), and Froom et al state that the Netherlands is the only country where only a minority of the episodes of Otitis Media are treated with antibiotics.

The outcome of ASOM does not seem to be any worse than in other countries. In addition, doctors are often uncertain about the diagnosis of Suppurative Otitis Media. Therefore, we recommend that clinicians should immediately reconsider the routine use of antimicrobials for children with Suppurative Otitis Media and consider treating symptoms with analgesics and observation for lack of improvement(12). In conclusion, azithromycin given for three days and co-Amoxiclav for 10 days had similar efficacy; however, Azithromycin was better tolerated.

 

REFERENCES
  1. O'Neill P.Clinical evidence: Acute otitis media. BMJ1999; 319:833-835.
  2. Prince A. Infections Diseases. In: Behrman RE, Kliegman RM, editors. Nelson essential of pediatrics. 4th edition, Saunders WB, USA. 2001; 10: 388-389.
  3. Arrieta A, Arguedas A, Fernandez P, et al. High-dose azithromycin versus high-dose amoxicillinclavulanate for treatment of children with recurrent or persistent acute otitis media. Antimicrob Agents Chemother2003; 47(10): 3179-3186.
  4. Kerr AG. Acute otitis media. In: Adams DA, Cinnamond MJ, editors. Scott-Brown's Otolaryngology. 6th edition, Arnold. 1996; 8: 220-221.
  5. Jacob A, Rupa V, Job A, Joseph A. Hearing impairment and otitis media in a rural primary school in south India. Int J Pediar Otohinolaryngol1997; 39(2): 133-138.
  6. Dunne MW, Latiolais T, Lewis B, et al. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media. J Antimicrob Chemother 2003; 52(3): 469-472.
  7. Kennell Toda. University of Wisconsin-Madison, Department of Bacteriology. 2002
  8. Foulds G, Shepard RM, Johnson RB, et al. The pharmacokinetics of Azithromycin in human serum and tissues. J Antimicrob Chemother1990; 25:73-82.
  9. Nahata MC, Koranyi KI, Luke DR, Foulds G.Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrobial Agents Chemotherapy1995; 39(8): 1875-1877.
  10. Parra A, Ponte C, Cenjor C, et al. Effect of antibiotic treatment delay on therapeutic outcome of experimental acute otitis media caused by Streptococcus pneumoniae strains with different susceptibilities to amoxicillin. Antimicrobial Agents Chemotherapy2004; 48(3): 860-866.
  11. Damoiseaux RAMJ, Van Balen FAM, Hoes AW, et al. Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years.BMJ2000; 320: 350-354.
  12. Froom J, Culpepper L, Grob P, et al. Diagnosis and antibiotic treatment of acute otitis media: Report from International Primary Care Network. BMJ 1990; 300: 582-586.
.................................................................................................................
 

I About MEJFM I Journal I Advertising I Author Info I Editorial Board I Resources I Contact us I Journal Archive I MEPRCN I Noticeboard I News and Updates
Disclaimer - ISSN 148-4196 - © Copyright 2007 medi+WORLD International Pty. Ltd. - All rights reserved